D
David M. Ross
Researcher at Royal Adelaide Hospital
Publications - 159
Citations - 4518
David M. Ross is an academic researcher from Royal Adelaide Hospital. The author has contributed to research in topics: Imatinib mesylate & Myeloid leukemia. The author has an hindex of 26, co-authored 141 publications receiving 3608 citations. Previous affiliations of David M. Ross include University of South Australia & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross,Susan Branford,John F. Seymour,Anthony P. Schwarer,Christopher Arthur,David T Yeung,David T Yeung,Phuong Dang,Jarrad M. Goyne,Cassandra Slader,Robin Filshie,Anthony K. Mills,Junia V. Melo,Junia V. Melo,Deborah L. White,Deborah L. White,Andrew Grigg,Timothy P. Hughes,Timothy P. Hughes +18 more
TL;DR: The results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse, and show persistence of the original CML clone in all patients with stable U MRD, even several years after imatinIB withdrawal.
Journal ArticleDOI
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Andrew Wylie,Joseph Schoepfer,Wolfgang Jahnke,Sandra W. Cowan-Jacob,Alice Loo,Pascal Furet,Andreas Marzinzik,Xavier Pelle,Jerry Donovan,Wenjing Zhu,Silvia Buonamici,A. Quamrul Hassan,Franco Lombardo,Varsha Iyer,Michael Palmer,Giuliano Berellini,Stephanie Kay Dodd,Sanjeev Thohan,Hans Bitter,Susan Branford,David M. Ross,Timothy P. Hughes,Lilli Petruzzelli,K. Gary Vanasse,Markus Warmuth,Francesco Hofmann,Nicholas Keen,William R. Sellers +27 more
TL;DR: Describing ABL001 (asciminib), a potent and selective allosteric ABL1 inhibitor that is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia, shows similar cellular potencies but distinct patterns of resistance mutations.
Journal ArticleDOI
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
David M. Ross,Susan Branford,John F. Seymour,Anthony P. Schwarer,Christopher Arthur,Paul A. Bartley,Cassandra Slader,Chani Field,Phuong Dang,Robin Filshie,Anthony K. Mills,Andrew Grigg,Junia V. Melo,Junia V. Melo,Timothy P. Hughes,Timothy P. Hughes +15 more
TL;DR: A highly sensitive patient-specific nested quantitative PCR assay for BCR–ABL1 provides evidence that even patients who maintain a CMR after stopping imatinib may harbor residual leukemia.
Journal ArticleDOI
Moving treatment-free remission into mainstream clinical practice in CML.
Timothy P. Hughes,David M. Ross +1 more
TL;DR: Competence in which it would be in the patient's best interest to continue TKI, as well as criteria for a safe TFR attempt are outlined, based on the evident safety of cessation attempts and TFR in the clinical trial setting.
Journal ArticleDOI
Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial.
David M. Simpson,Justin C. McArthur,Richard K. Olney,David B. Clifford,Yuen T. So,David M. Ross,B. J. Baird,P. Barrett,Anne E. Hammer,Richard S. Baker,Russell Bartt,S. Becker,Joseph R. Berger,Thomas H. Brannagan,Bruce A. Cohen,C. Dorko,Ronald J. Ellis,D. M. Feinberg,K. Goodkin,Colin D. Hall,Princy Kumar,Camillo Marra,Richard B. Pollard,Giovanni Schifitto,Alex Tselis,K. Vollmer +25 more
TL;DR: Lamotrigine was well-tolerated and effective for HIV-associated neuropathic pain in patients receiving neurotoxic antiretroviral therapy, and patient and clinician ratings of global impression of change in pain were similar.